Raptor Pharmaceutical Corp. announced positive Phase 2a clinical trial results from its pilot study of delayed-release cysteamine bitartrate in 11 adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver disease believed to affect 5% to 11% of the U.S. population. more
To use all functions of this page, please activate cookies in your browser.
